News
We provide the latest news from the world of economics and finance
(RTTNews) - Santhera Pharmaceuticals Holding AG (SANN.SW, SPHDF), a Swiss specialty pharmaceutical company, on Tuesday appointed Marc Clausse as Chief Commercial Officer effective June 1.
Chief Commercial Officer Geert Jan van Daal will retire after 11 years with the company on the same date.
Clausse will take over from Daal and will lead the company's next phase of commercial growth.
Geert Jan van Daal will remain available over the coming months to support an orderly transition.
Clausse brings more than 25 years of international experience in the life sciences industry across specialty, oncology and rare diseases.
Most recently, Clausse served as Vice President of International Strategy & Operations and UK General Manager at Mirum Pharmaceuticals.
On Monday, Santhera Pharma closed trading 3.92% higher at CHF 15.90 on the Swiss Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2026 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@j2t.com
